Artemisa pollen-specific immumoglobulins (IgG4, IgG and IgE) were evaluated by means of ELISA during rush immunotherapy in 49 patients with pollinosis. The results showed that six weeks after the beginning of immunotherapy, the levels of specific IgG4(P < 0.05) and IgG (P < 0.001) antibodies were significantly higher than those of patients prior to receiving rush immunotherapy. These results suggest that rush immunotherapy may result in a rapid increase in IgG antibody levels, and high specific IgG level may implicate a clinical improvement in allergic patients due to the rush immunotherapy.